Allergan Rating Reiterated by Zacks (AGN)

Share on StockTwits

Zacks reaffirmed their outperform rating on shares of Allergan (NYSE:AGN) in a research note issued to investors on Thursday, AR Network reports. The firm currently has a $138.00 price target on the stock.

Zacks has also taken action a number of other healthcare stocks recently. The firm downgraded shares of Sagent Pharmaceuticals Inc. from an outperform rating to a neutral rating. Their analysts now have a $22.70 price target on that stock. Also, Zacks reiterated its neutral rating on shares of Perrigo Co.. They have a $154.00 price target on that stock. Finally, Zacks reiterated its neutral rating on shares of AbbVie Inc.. They have a $50.00 price target on that stock.

Allergan (NYSE:AGN) traded up 0.43% during mid-day trading on Thursday, hitting $117.88. 1,382,405 shares of the company’s stock traded hands. Allergan has a one year low of $81.33 and a one year high of $123.83. The stock has a 50-day moving average of $113.9 and a 200-day moving average of $97.19. The company has a market cap of $35.029 billion and a P/E ratio of 35.58.

Allergan (NYSE:AGN) last announced its earnings results on Tuesday, February 4th. The company reported $1.12 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.34 by $0.22. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.65 million. During the same quarter last year, the company posted $1.15 earnings per share. Allergan’s revenue was up 14.4% compared to the same quarter last year. On average, analysts predict that Allergan will post $5.45 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Friday, March 21st. Shareholders of record on Friday, February 28th will be given a dividend of 0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.17%. The ex-dividend date of this dividend is Wednesday, February 26th.

Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup Inc. upgraded shares of Allergan from a neutral rating to a buy rating in a research note to investors on Tuesday. They now have a $130.00 price target on the stock, up previously from $95.00. Separately, analysts at SunTrust upgraded shares of Allergan from a neutral rating to a buy rating in a research note to investors on Friday, January 17th. They now have a $150.00 price target on the stock, up previously from $94.00. Finally, analysts at Morgan Stanley reiterated an equal weight rating on shares of Allergan in a research note to investors on Wednesday, January 15th. They now have a $94.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of Buy and an average price target of $118.10.

Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.

To view Zacks’ full report, visit www.zacks.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Proctor & Gamble Trimming Costs, Sales Fall
Proctor & Gamble Trimming Costs, Sales Fall
Netflix Set to Increase Subscription Price
Netflix Set to Increase Subscription Price
Hasbro Profit Helped by Girls Toys
Hasbro Profit Helped by Girls Toys
LinkedIn Reaches Milestone of 300 Million Members
LinkedIn Reaches Milestone of 300 Million Members
IBM Revenues Disappoint For Another Quarter
IBM Revenues Disappoint For Another Quarter
Walmart Enters the Business of Money Transfers
Walmart Enters the Business of Money Transfers


Leave a Reply

 
 
© 2006-2014 Ticker Report. Google+. Subscribe
X

Receive Analysts' Upgrades and Downgrades in Your Inbox Daily